PubRank

Michael Ashton

Author PubWeight™ 32.89‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 2007 2.68
2 Pitfalls in estimating piperaquine elimination. Antimicrob Agents Chemother 2005 1.79
3 Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria. Eur J Clin Pharmacol 2002 1.38
4 Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects. Eur J Clin Pharmacol 2006 1.31
5 A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction. Br J Clin Pharmacol 2005 1.28
6 Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania. Antimicrob Agents Chemother 2010 1.27
7 The influence of food on the pharmacokinetics of piperaquine in healthy Vietnamese volunteers. Acta Trop 2008 1.19
8 Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens. Antimicrob Agents Chemother 2002 1.18
9 Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria. J Pharmacokinet Pharmacodyn 2007 1.16
10 Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. Clin Pharmacol Ther 2003 1.07
11 Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects. Fundam Clin Pharmacol 2007 1.04
12 In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. Br J Clin Pharmacol 2011 0.98
13 A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan. Malar J 2012 0.97
14 Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications. Br J Clin Pharmacol 2015 0.96
15 Knowledge about sexually transmitted diseases in women among primary care physicians. Sex Transm Dis 2005 0.94
16 Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapy. AAPS J 2011 0.92
17 Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer. Eur J Clin Pharmacol 2014 0.92
18 Artemisinin and CYP2A6 activity in healthy subjects. Eur J Clin Pharmacol 2007 0.90
19 Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis. Eur J Clin Pharmacol 2002 0.90
20 Population pharmacokinetic modeling and deconvolution of enantioselective absorption of eflornithine in the rat. J Pharmacokinet Pharmacodyn 2013 0.87
21 A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens. J Pharmacokinet Pharmacodyn 2008 0.83
22 Characterisation of the human liver in vitro metabolic pattern of artemisinin and auto-induction in the rat by use of nonlinear mixed effects modelling. Biopharm Drug Dispos 2003 0.82
23 Orally formulated artemisinin in healthy fasting Vietnamese male subjects: a randomized, four-sequence, open-label, pharmacokinetic crossover study. Clin Ther 2011 0.82
24 Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study. Am J Nephrol 2004 0.80
25 HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects. Clin Pharmacokinet 2011 0.80
26 PXR variants and artemisinin use in Vietnamese subjects: frequency distribution and impact on the interindividual variability of CYP3A induction by artemisinin. Antimicrob Agents Chemother 2012 0.79
27 The evaluation of CYP2B6 inhibition by artemisinin antimalarials in recombinant enzymes and human liver microsomes. Drug Metab Lett 2012 0.77
28 Effects of artemisinin antimalarials on Cytochrome P450 enzymes in vitro using recombinant enzymes and human liver microsomes: potential implications for combination therapies. Xenobiotica 2014 0.77
29 Prediction of drug tissue to plasma concentration ratios using a measured volume of distribution in combination with lipophilicity. J Pharm Sci 2008 0.77
30 External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients. AAPS J 2012 0.77
31 Artemisinin--a possible CYP2B6 probe substrate? Biopharm Drug Dispos 2009 0.76
32 A rapid and selective HPLC-UV method for the quantitation of efavirenz in plasma from patients on concurrent HIV/AIDS and tuberculosis treatments. Biomed Chromatogr 2013 0.76
33 Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients. J Pharmacokinet Pharmacodyn 2011 0.75
34 A high-throughput LC-MS/MS assay for quantification of artesunate and its metabolite dihydroartemisinin in human plasma and saliva. Bioanalysis 2014 0.75
35 The Vietnamese Khin population harbors particular N-acetyltransferase 2 allele frequencies. Clin Chem 2007 0.75
36 Effects of oral administration of synthesized delta-amides of eflornithine in the rat. Arzneimittelforschung 2010 0.75
37 Mono-, di- and trisubstituted derivatives of eflornithine: synthesis for in vivo delivery of DL-alpha-difluoromethylornithine in plasma. Arzneimittelforschung 2011 0.75
38 Simultaneous enantiospecific separation and quantitation of mephenytoin and its metabolites nirvanol and 4'-hydroxymephenytoin in human plasma by liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2003 0.75